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Abstract
Purpose: Sentinel lymph node (SLN) is the first regional node that drains lymph from the primary tumour and 
receives seeding of metastatic cells. Axillary node dissection remains the most reliable predictor of disease outcome. 
Controversies still exist about several aspects of lymphatic mapping and SLN biopsy for breast cancer, including 
number of radioisotope injection. The purpose of this study is to evaluate the success rate of different number of 
injection sites in the detection of SLN in breast cancer.
Materials and Methods: A total of 120 consecutive breast cancer patients were divided into two groups. Group A 
(60 patients) received four intradermal periareolar (ID-PA) injections. Group B (60 patients) received two ID-PA injections. 
Imaging was carried out at 45 min post-injection. A gamma probe was used to explore the SLNs during surgery.
Results: In Group A, 60 females with the mean age of 50.77 years were included in the study. 34 (56%) patients 
had single SLN. 25 (41.7%) had SLN with the second tier. 1 (1.7%) was negative. Group B included 60 patients 
(59 females and 1 male) with the mean age of 51.9 years. In 30 (50%) patients, single SLN was detected. 29 (48.3%) 
had SLN with the second tier. 1 (1.7%) was negative.
Conclusion: SLN mapping with two periareolar ID injections carries less radiation dose and less pain as compared to 
the four injections with equal sensitivity for the visualization of SLNs.
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Introduction
Breast cancer is the most common malignancy of females 
all over the world and the second leading cause of death 
due to cancer among females. Approximately one in every 
nine Pakistani women is likely to suffer from breast cancer. 
This is one of the highest incidence rates in Asia.[1]
Sentinel lymph node (SLN) is the first regional lymph 
node that drains the lymph from the primary tumour.[2] It is 
potentially the first node to receive the seeding of lymph-
borne metastatic cells. Axillary lymph node dissection 
remains one of the mainstays of breast cancer because 
clinical, imaging or laboratory methods are insufficient to 
define nodal status, the most reliable predictor of disease 
outcome.[3] SLN biopsy is a standard practice in most centres.
The morbidity associated with an axillary procedure 
includes arm swelling, sensory disturbance, infection, 
shoulder stiffness and impaired shoulder movement.[4] 
The ideal situation, therefore, would be to stage the 
axilla with no or minimal intervention. SLN scintigraphy 
allows the surgeon to easily identify and biopsy the 
SLN, and it can be performed under local anaesthesia 
in an attempt to reduce the risks of general anaesthetics. 
At present, detection of SLN is highly accurate in 
the context of carcinoma breast and there is rapidly 
increasing database population. SLN mapping (SLNM) 
is a technique in which a radioactive tracer is injected 
into the breast and a molecular imaging scan is performed 
to provide a ‘road map’ of lymphatic drainage from the 
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tumour.[5] However, there are still ongoing controversies 
about several aspects of lymphatic mapping and SLN 
biopsy for breast cancer, including number of injection 
sites of radioisotope.[6] This study aims to evaluate the 
success rate of different number of the intradermal 
periareolar (ID-PA) injection sites in the detection of 
SLN in breast cancer. No such study has been carried 
out in the Pakistani population.
Materials and Methods
Retrospective data collection was done over a period of 
6 months from October 2013 to March 2014. 120 consecutive 
patients were enrolled. Patients of any gender and any age 
with biopsy-proven breast carcinoma and no clinically 
palpable axillary lymph nodes were included in the study.
Patients with primary tumour >5 cm, local recurrence and 
pre-operative chemotherapy/radiotherapy were excluded 
from the study.
Breast lymphoscintigraphy for SLN localization was 
performed in the evening before surgery. Radiopharmaceutical 
used was 99mTc-labelled human albumin colloid particles 
(99mTc-HSA nanocolloids) 20 MBq/injection site, in 
a volume of 0.2 ml. The patients were divided into two 
groups by simple random sampling. Aseptic technique was 
used for injection. Group A (60 patients) received four ID-
PA injections at 3, 6, 9 and 12’0 clock positions. Group B 
(60 patients) received two ID-PA injections at 6 and 12’0 
clock positions. Scintigraphic images were acquired 45 min 
and 16 h post-injection (p.i.) by a gamma camera (Infinia; GE 
Medical Systems, Milwaukee, WI, USA) equipped with a 
low-energy general purpose collimator with energy window 
set at 140 KeV. Static left/right anterior, oblique (30°) and 
lateral views were performed (128 × 128 matrix, zoom 1.0) 
on a time-based (2 min each view) study. Delayed imaging 
was done next morning before surgery, but not later than 
18 h post-injection. The first lymph node to be visualized on 
gamma camera scan is referred to as SLN. The node receiving 
radiotracer from other node is referred to as the second tier 
node. A surgical gamma probe was used to explore the SLNs 
during surgery along with blue dye injection intraoperatively.
Statistical analysis
All data were entered and assessed using computer-based 
Statistical Package for the Social Sciences version 19. The 
mean ± SD was calculated for quantitative variables like 
age. Qualitative variables such as gender and detection of 
SLN are presented in percentages and frequency.
Chi-square test was used to compare the detection of SLN 





In Group A, a total of 60 patients were included in the 
study. All of them were females with the mean age of 
50.77 years and the age range was 31–80 years (SD ± 11.8).
Group B
Group B included total of 60 patients, of which only 
1 (1.6%) was male while the remaining 59 (98.4%) were 
females. Mean age was 51.90 years and the age range was 
30–80 years (SD ± 10.3).
Sentinel node localization in Groups A and B
Group A
In 34 (56%) patients, single SLN was detected, and in 
25 (41.7%), SLN with the second tier was visualized. In 
1 patient (1.7%), no SLN was visualized [Figure 1].
Group B
In 30 (50%) patients, single SLN was detected, and in 
29 (48.3%), SLN with the second tier was visualized. In 
1 patient (1.7%), no SLN was visualized [Figure 1].
Comparison of sentinel node localization in Groups A 
and B
There was no statistically significant difference between 
the results of two-injection techniques (P = 0.761).
Discussion
Breast cancer is the most common malignancy among 
females and the second leading cause of cancer-related 
deaths. Pakistan has one of the highest incident rates 
in Asia with every ninth women likely to suffer from 
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breast cancer.[1] The first lymph node in the lymphatic 
basin draining the primary tumour is called the SLN.[7] 
It reflects the histological characteristics of the rest of 
the nodes in the chain. The metastases to lymph node 
are not a random phenomenon and can be determined 
by identifying the lymph flow from tumour to primary 
lymph draining node.
Satisfactory results are obtained with SLNB despite 
significant variations in the methodology. Some centres use 
blue dye only, others use radiocolloid (Tc99 sulphur colloid), 
only but most of the centre use combination of two for the 
detection of SLNB. All three methods had reliable results in 
experienced hands. Many authors demonstrated best results 
with combination techniques proving that this hypothesis 
is true. Of 39 studies, using radioisotopes (16 studies) or 
blue dye (11 studies) or a combination of both (12 studies) 
identified SLN in 92%, 81% and 93%, respectively.[8]
Different injection techniques are applied for the injection 
of radiotracer and blue dye in patients with primary 
breast lesion for SLNB. Peritumoural or intratumoural 
injection technique was used in initial studies of SLNB 
for following reasons; first, the lymphatic drainage of 
the skin of the breast and glandular tissue was thought 
to be different, and second, the injection distant from 
tumour may not represent true SLN.[9,10] Many recent 
studies use ID, subdermal (SD) and subareolar (SA).[11-13] 
Several authors demonstrated that visualization of axillary 
lymph nodes by ID or SA injection is faster than with 
peritumoural PT injection.[13-16] Most of the studies 
reported, SLN identification >95% in appropriately 
selected patients.[17-20] The detection rate in both the 
groups of this study is 98.33% which is in line with the 
meta-analysis of previous literature.[17-20] Also noted is the 
fact that there is no significant difference (P = 0.546) in 
the frequency of detection of SLNs in both groups with 
different number of radiotracer injections. Hence, the 
frequency of the detection of SLN using two-injection 
technique is comparable four-injection technique in 
patients with breast carcinoma. Furthermore, more number 
of the second tier nodes is identified in the two-injection 
technique as compared to the four injections, which 
signifies that the visualization of the second tier nodes is 
not related to the number of injection sites. However, it 
is of clinical importance that the radiation dose as well 
as the pain is less in case of two injections (Group B) as 
opposed to four injections (Group A).
Many factors can affect visualization of the sentinel node 
during lymphoscintigraphy. In advanced breast cancer, 
lymphatics become progressively infiltrated with tumour 
cells and do not allow the passage of radionuclides.[21] 
Cancerous involvement of the lymphatic system may 
influence the drainage pattern.
Completely invaded nodes may lead to unsuccessful axillary 
node detection due to a lack of ability of tracer uptake in 
the leading node. Heuser et al. reported five cases in which 
no axillary SN could be detected and consecutive axillary 
surgery revealed a positive nodal status in four of these 
patients with unsuccessful mapping.[22] The two patients in 
our study with negative sentinel scan underwent surgery 
after blue dye labelling. One out of these patients had nodal 
involvement by the tumour while the other had nodes 
negative for malignancy.
It has previously been reported that the age of the patient and 
tumour size may influence sentinel node detection rates.[23] 
Furthermore, the radiopharmaceutical used, the dose of the 
pharmaceutical, the particle size of the pharmaceutical and 
the injection-to-imaging time may all influence visualization 
of the sentinel node during lymphoscintigraphy.[24] The site 
of pharmaceutical injection (whether intratumoural vs. 
extratumoural, ID vs. SD or lateral vs. medial to a previous 
breast scar) can also affect visualization of the sentinel node 
during lymphoscintigraphy.[25]
Figure 1: Results of sentinel node visualization in Groups A 
and B
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Limitations
There are few limitations and possible biases in our study.
• As in any other cross-sectional study, we could not 
exclude the possibility of referral bias that influenced 
our study.
• The study was conducted over a short period of 
time. Further studies with larger sample size may be 
conducted.
• Difference in expertise level of injecting physician 
may also be a cause of variability in results.
Conclusion
Sentinel lymph node mapping with two periareolar 
intradermal injections carries less radiation dose and 
less pain as compared to the four injections with equal 
sensitivity for the visualization of sentinel lymph nodes.
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